A Phase I Study of IMGN529 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma

Full Title

A Phase I, Multi-center, Open-label Study of IMGN529 Administered Intravenously in Adult Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia


The purpose of this study is to find the highest dose of an investigational drug called IMGN529 that can be given safely in patients with B-cell non-Hodgkin lymphoma (NHL) that has returned or continued to grow despite standard therapy.

IMGN529 is composed of two parts: an antibody that binds to a protein on lymphoma cells called CD37, and a chemotherapy drug called DM1 which is transported by the antibody and causes cancer cells to die. IMGN529 is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have NHL that has returned or continued to grow despite standard therapy that included rituximab.
  • Patients with T-cell lymphoma may not participate.
  • There is no limit on the number of prior treatments, but patients should have recovered from the serious side effects of therapy before entering the study.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. M. Lia Palomba at 212-639-7186.







Zelenetz, Andrew, MD, PhD